Epitalon: A Synthetic Tetrapeptide and the State of Its Evidence

Epitalon, transliterated elsewhere as epithalon or epithalone, is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. The chemistry is simple and the molecule is short. The literature built around it is neither, and reading that literature well takes more care than handling the compound does.

Identity, and the several spellings

The molecule is Ala-Glu-Asp-Gly, AEDG in one-letter code. Formula C14H22N4O9, molecular mass 390.35 g/mol, CAS 307297-39-8.

It circulates in both the literature and the market as Epithalon, Epitalon, Epithalone and “AEDG peptide”. Every one of those indexes the same molecule, which is worth knowing when searching and is precisely why the registry number is the identifier to quote.

At four residues it is among the smallest compounds in this category, and the consequences of that are practical rather than theoretical.

Its origin as a defined synthetic sequence

Epitalon was developed as a synthetic counterpart to epithalamin, a peptide preparation extracted from bovine pineal gland. Extracts are heterogeneous by nature, and part of the point of producing a defined synthetic sequence was to have a single characterized molecule in hand rather than a mixture. The two are not interchangeable in the literature: a paper on epithalamin is not evidence about epitalon and should not be cited as though it were.

The shape of the published record

Anyone evaluating this compound should understand how its literature is structured, because that structure bears directly on how much weight any individual finding can carry.

A large share of the primary work traces back to a small number of affiliated research groups, and much of it appeared in Russian-language journals with limited indexing in Western databases, some of it decades ago. Independent replication outside that lineage is comparatively sparse. Several frequently cited items are conference abstracts or review summaries rather than full primary papers with complete methods. Study designs tend to be small, the reported endpoints span a wide range of biological measures rather than converging on any single mechanism, and no specific receptor has been established for the molecule.

None of that demonstrates the reported findings are wrong, and none of it renders the literature worthless. What it does is disable the usual heuristic. Ordinarily a claim repeated across many citations is taken to be well supported; here repeated citation can trace back through a handful of original sources, so citation count is measuring circulation rather than corroboration.

The practical reading follows directly. Treat published effect claims as hypotheses generated within one tradition rather than as settled results, and ask specifically whether a given result has been reproduced by a group unconnected to the original. For a molecule this small and this easy to synthesize, independent replication is cheap, which makes its relative absence informative in itself.

The indexed literature is at PubMed, and a search for AEDG peptide surfaces additional records filed under the sequence abbreviation. On why a reported figure without its assay system attached cannot be compared with another one, see what binding and potency figures actually measure.

Short peptides are easier to verify

Analytical confidence runs inversely to chain length, and this compound sits at the favorable end of that scale.

• Few synthesis cycles. Four residues means roughly four couplings rather than thirty-nine, leaving far less room for a deletion sequence, which is the impurity class a purity percentage most readily conceals in a long peptide.
• An unambiguous mass spectrum. At 390 Da the target peak is clear, and losing any single residue is a proportionally enormous mass change. Dropping the glycine alone removes 57 Da, close to 15% of the molecule. Nothing subtle hides in a shift that size.
• Short retention. A small, highly polar peptide leaves a reverse-phase column early, which separates it cleanly from most hydrophobic process impurities.

A certificate reporting observed mass against theoretical mass is therefore unusually strong evidence for this compound. The same document tells you considerably less about a 39-residue peptide. See where peptide impurities come from.

The single liability the sequence carries

Read the composition again: alanine, glutamate, aspartate, glycine. That Asp-Gly pair at the C-terminal end is the classic deamidation and isomerization motif of peptide chemistry. Aspartate followed by glycine is the most reactive arrangement available for succinimide formation, which converts aspartate into isoaspartate, a rearrangement that alters structure while leaving mass essentially unchanged.

That is the impurity to watch here, and mass spectrometry will not find it. Either it resolves chromatographically or it does not resolve at all. The reaction runs faster in solution than in the dry state, faster warm than cold, and its rate depends on pH. Those three facts are the entire practical argument for keeping material lyophilized and refrigerated and for not leaving reconstituted solution standing on a bench. See storage and stability and limiting repeat vial entry.

What the sequence does not contain is methionine, cysteine or tryptophan, so no oxidation route is open to it at all. One liability rather than several.

Analytical behavior at the small end

Four residues and roughly 390 daltons places epitalon near the lower size limit for conventional peptide analysis, which has two consequences.

Short, highly polar sequences are poorly retained on standard C18 reversed-phase columns and can elute close to the void volume, where separation from small-molecule impurities is weakest. Analysts commonly move to aqueous-compatible stationary phases or adjust ion-pairing to handle that.

The two acidic residues make the peptide strongly anionic at neutral pH and highly water-soluble. Reconstitution is easy as a result, but counterion content takes up a larger share of gross weight than it would in a longer sequence. On a 390 Da molecule a trifluoroacetate counterion is a substantial fraction of total mass, and that matters every time a vial weight is converted into a molar concentration. See net peptide content explained and counterions and salt form.

What to look for on a certificate

Since the molecule is small and straightforward to make, the sourcing question is not really whether a supplier can produce it. It is whether they can show you what they produced. Three things to check:

• Observed mass reported against theoretical mass.
• The detection wavelength stated alongside the purity figure. A tetrapeptide with no aromatic residues is badly under-reported at 280 nm and should be measured at 214 nm.
• Net peptide content, for the counterion reason set out above.

Further background: how to read a certificate of analysis and peptide nomenclature.

Product

Product page: Epitalon 10mg.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use.